Gubra A S

Welcome to the conference call. For the first part of the conference call, the participants will be in listen-only mode. During the questions and answers session, participants are able to ask questions by dialing pound key 5 on their telephone keypad. Now I will hand the conference over to the speakers. Please go ahead.

Good morning, everyone, and welcome to Gruber's conference call covering the third quarter of 2026. My name is Adam Lange, Head of Investor Relations at Groupon and joining me today are members of Groupon's leadership team who will walk you through the key developments during the quarter and discuss our financial performance. We'll do a presentation expected to last approximately 20-25 minutes and we'll then afterwards open the call for questions. Now on slide 2, I need to remind everyone that today, during the presentation and the subsequent Q&A session, we may make forward-looking statements that are subject to risks and uncertainties. And with that, I will hand over the call to our CEO, Markus Rohrwild, for opening remarks.

Good morning. Welcome from my side. Q3 has been very strong for GoPra. We have significant advancements in our R&D pipeline, and we have also seen strong CO performance. On the biotech side, our two partner obesity programs advanced to phase two, a great achievement for Gupra. And also, we're excited to see our group UCM2, EUROCROTIN2 analog entering phase one clinical development. Moreover, the CRO has shown 6% growth year on year and our EBIT margin has significantly improved to 25%, which is great. On top of that, we are actively evaluating multiple opportunities on the venture side to augment our innovation pipeline. You have probably participated in our recent R&D investor event and I'd like to again summarize our ambition for 2030. As we are scaling our differentiated drug discovery and development platform by 2030, we would like to see 8 to 10 clinical assets in our Pipeline as well as also bringing forward one to two drug development candidates from our internal drug discovery unit every year. Moreover, we will be expanding our therapeutic flagship areas from our stronghold in metabolic diseases and obesity towards functional decline as well as inflammation and immunology. In addition, the company will create value by launching two to three ventures as well as continuing operating a growing specialist preclinical COO under high profitability. And with this, I hand over to the biotech unit, Louise.